Table 4.
Antisecretory medications used for patients with short bowel syndrome.
| Medication Class | Usage Median (Range, %) |
Medications | Initial Dose Median (Range, mg/day) |
Maximum Dose Median (Range, mg/day) |
Dose Recommendation per Label (mg/day) |
|---|---|---|---|---|---|
| Proton-pump inhibitor (first-line) |
80 (0–100) | Pantoprazole | 40 (20–80) | 80 (40–160) | 20–40 mg BID |
| Omeprazole | 40 (20–80) | 80 | 20–40 mg BID | ||
| Esomeprazole | 80 | 80 | 20–40 mg BID | ||
| Lansoprazole | 60 | 60 | 15–30 BID | ||
| H2RA (oral) | 10 (0–30) | Famotidine | 40 (20–80) | 40 (20–80) | 20–40 mg BID |
| Ranitidine | 300 | 300 | 150–300 mg BID | ||
| Nizatidine | 150 | 300 | 150–300 mg BID | ||
| Somatostatin analogue | 10 (0–50) | Octreotide | 300 (150–600) μg | 600 (300–1500) μg | 50–250 μg SC TID or QID |
| H2RA (added to PS) | 0 (0–90) | Famotidine | 40 (20–80) | 40 (20–80) | 20–40 mg BID |
Abbreviations: mg, milligram; H2RA, histamine 2-receptor antagonists; BID, two times a day; TID, three times a day; QID, four times a day; PS, parenteral support.